Abstract:Patient‐derived xenografts models more closely resemble patient samples in tumour heterogeneity and cell cycle characteristics when compared with cell lines. 3D organoid models exhibit differences in metabolic profiles compared to their in vivo counterparts. A valuable multimodel reference dataset that can be useful in elucidating model differences and novel targetable pathways. Background Breast cancer's complex transcriptional landscape requires an improved understanding of cellular diversity to identify effective treatments. The study of genetic variations among breast cancer subtypes at single‐cell resolution has potential to deepen our insights into cancer progression. Methods In this study, we amalgamate single‐cell RNA sequencing data from patient tumours and matched lymph metastasis, reduction mammoplasties, breast cancer patient‐derived xenografts (PDXs), PDX‐derived organoids (PDXOs), and cell lines resulting in a diverse dataset of 117 samples with 506 719 total cells. These samples encompass hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+), and triple‐negative breast cancer (TNBC) subtypes, including isogenic model pairs. Herein, we delineated similarities and distinctions across models and patient samples and explore therapeutic drug efficacy based on subtype proportions. Results PDX models more closely resemble patient samples in terms of tumour heterogeneity and cell cycle characteristics when compared with TNBC cell lines. Acquired drug resistance was associated with an increase in basal‐like cell proportions within TNBC PDX tumours as defined with SCSubtype and TNBCtype cell typing predictors. All patient samples contained a mixture of subtypes; compared to primary tumours HR+ lymph node metastases had lower proportions of HER2‐Enriched cells. PDXOs exhibited differences in metabolic‐related transcripts compared to PDX tumours. Correlative analyses of cytotoxic drugs on PDX cells identified therapeutic efficacy was based on subtype proportion. Conclusions We present a substantial multimodel dataset, a dynamic approach to cell‐wise sample annotation, and a comprehensive interrogation of models within systems of human breast cancer. This analysis and reference will facilitate informed decision‐making in preclinical research and therapeutic development through its elucidation of model limitations, subtype‐specific insights and novel targetable pathways. Key points Patient‐derived xenografts models more closely resemble patient samples in tumour heterogeneity and cell cycle characteristics when compared with cell lines. 3D organoid models exhibit differences in metabolic profiles compared to their in vivo counterparts. A valuable multimodel reference dataset that can be useful in elucidating model differences and novel targetable pathways.

Multi-omics Analysis of Primary Cell Culture Models Reveals Genetic and Epigenetic Basis of Intratumoral Phenotypic Diversity.

Abstract 208: Multi-omics Analysis in Primary Cell Cultures Reveals the Genomic Basis of Phenotypic Diversity Within Tumors

Using Single‐cell Multiple Omics Approaches to Resolve Tumor Heterogeneity

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

A CNV Computational Model for Clonal Origin Analysis of Synchronous Multifocal Hepatobiliary and Pancreatic Tumors.

Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.

Single Cell Multi-Omics Reveal Intra-Cell-line Heterogeneity Across Human Cancer Cell Lines

Single-cell Multiomics Sequencing and Analyses of Human Colorectal Cancer

Single‐cell transcriptional atlas of human breast cancers and model systems

Single cell atlas reveals multilayered metabolic heterogeneity across tumour types

Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine

Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Intra-tumour diversification in colorectal cancer at the single-cell level

Single-cell genomic variation induced by mutational processes in cancer

Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma

Colorectal Cancer Patient‐Derived 2D and 3D Models Efficiently Recapitulate Inter‐ and Intratumoral Heterogeneity

Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers

Integrative Analysis of Two Cell Lines Derived from a Non-Small-Lung Cancer Patient - A Panomics Approach.

Decoding Liver Cancer Prognosis: From Multi-omics Subtypes, Prognostic Models to Single Cell Validation

Clinical significance of heterogeneity in multifocal hepatocellular carcinoma:A multi-omics study

Many Are Called but Few Are Chosen – Multiple Clonal Origins Greatly Elevate the Functional Heterogeneity of Tumors